All In Biotech

Drug Trial Radar · NCT07629960

A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

A Phase 1/2, Open-Label, Dose-Escalation, Dose-Enrichment, and Dose-Expansion Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of BLU-924 (SAR449336) as Monotherapy and Combination Therapy in Participants With Advanced Pancreatic Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer Harboring KRAS Mutations

Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

265

Planned (sponsor's estimate)

Start

Jun 4, 2026

Primary completion

Sep 2029

Study completion Jul 2031

Sponsor

Sponsor type
Industry
Collaborators
Sanofi
First posted
Jun 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A first in human study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of BLU-924 / SAR449336, a pan-KRAS inhibitor, in participants with advanced Pancreatic Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer harboring KRAS mutations.

Conditions

  • Advanced Solid Tumor
  • Non-Small Cell Lung Cancer
  • Colorectal Neoplasms
  • Pancreatic Ductal Adenocarcinoma

Interventions

  • BLU-924Drug

    Tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Escalation and Enrichment: Percentage of Participants with Dose-limiting Toxicity (DLTs)Time frame: Up to 5 years
  2. Dose Escalation, Enrichment and Expansion: Incidence and Severity of Treatment-emergent Adverse Events (TEAEs) and Serious AEsTime frame: Up to 5 years
  3. Dose Escalation and Enrichment: Maximum Tolerated Dose (MTD) of BLU-924Time frame: Up to 5 years
  4. Dose Escalation and Enrichment: Recommended Dose for Expansion (RDFE) of BLU-924Time frame: Up to 5 years
  5. Dose Expansion: Overall Response Rate (ORR)Time frame: Up to 5 years

Locations

16 sites in 2 countries. Site status is shown where the registry gives one.

  • Florida Cancer Specialists & Research Institute - Sarasota

    Sarasota, Florida · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • Mary Bird Perkins Cancer Center

    Baton Rouge, Louisiana · Not yet recruiting

  • Massachusetts General Hospital - Main Campus

    Boston, Massachusetts · Not yet recruiting

  • University of Michigan Medical School Rogel Cancer Center

    Ann Arbor, Michigan · Not yet recruiting

  • Hackensack University Medical Center

    Hackensack, New Jersey · Not yet recruiting

  • NYU Langone Health Perlmutter Cancer Center

    New York, New York · Not yet recruiting

  • Tennessee Oncology, PLLC

    Nashville, Tennessee · Not yet recruiting

  • The University of Texas MD Anderson Cancer Center - Texas Medical Center

    Houston, Texas · Not yet recruiting

  • Next Oncology Virginia Cancer Specialist

    Fairfax, Virginia · Recruiting

  • Mi Cancer Center Barcelona (Pratia Sirius Barcelona)

    Barcelona, Catalonia, Spain · Not yet recruiting

  • Hospital Universitario Vall d'Hebron

    Barcelona, Catalonia, Spain · Not yet recruiting

  • Hospital General Universitrio Gregorio Maranon

    Madrid, Madrid, Spain · Not yet recruiting

  • Hospital Universitario 12 de Octubre

    Madrid, Madrid, Spain · Not yet recruiting

  • NEXT Oncology - Madrid

    Pozuelo de Alarcón, Madrid, Spain · Not yet recruiting

  • Clinica Universidad de Navarra (CUN)

    Pamplona, Navarre, Spain · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.